IGC aims to pave way to new Alzheimer's treatments with cannabis-based combos

15 June 2017

Alzheimer's disease is a devastating brain disorder that now affects about 5.3 million Americans, accounting for one in nine people over the age of 65, according to the Alzheimer's Association, while treatments to slow or stop the disease's progression have been lacking.

Several pharmaceutical companies are working to change that. Among these is USA-based India Globalization Capital (NYSE: IGC), which has products that are backed by data of cannabis-based combination therapies to treat Alzheimer's, pain, seizures and a host of neurological and oncological issues, and is lined up with Biogen (Nasdaq: BIIB), Anavex Sciences (Nasdaq: AXON), and AC Immune (Nasdaq: ACIU) to develop medications they hope will yield promising results in treating a difficult and hard to treat illness.

The cost to the US economy from Alzheimer's disease is estimated at $236 billion, including the costs of caring for individuals with the illness. Without effective treatments, the economic impact will continue to climb.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK